The phase Ib/II Study 111 examining the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) in women with metastatic endometrial carcinoma has been expanded based on positive interim results, according to Eisai, the manufacturer of lenvatinib.
Endometrial carcinoma is the sixth most common cancer in women worldwide, with 320,000 new cases diagnosed in 2012. In the United States, it is estimated that there will be 60,000 new cases and 10,000 deaths attributed to the disease in 2017. There currently is no drug approved for second-line therapy.
Makker V, Rasco DW, Dutcus CE, et al. A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. J Clin Oncol. 2017;35 (suppl; abstr 5598).
... to read the full story